Allergan Funding SCS is a securitization vehicle established by Allergan, a pharmaceutical company, to finance its operations and acquisitions, typically utilizing the cash flow generated from its product sales to repay investors.
This financial analysis details the recently matured EUR-denominated bond (ISIN: XS1909193150) issued by Allergan Funding SCS, a dedicated financing vehicle associated with Allergan plc, a prominent global pharmaceutical company historically renowned for its contributions across various therapeutic areas including aesthetics, ophthalmology, and neuroscience, prior to its acquisition by AbbVie. Originating from the United States, this specific debt instrument carried an interest rate of 1.5% and represented a total issuance size of EUR 66,772,000, with a minimum purchase threshold set at EUR 100,000 per lot. Critically, the bond, which was trading at 100% of its par value on the market, successfully reached its scheduled maturity date of November 14, 2023, and has since been fully redeemed, concluding its lifecycle with its single annual interest payment frequency throughout its tenure.
|
Français
Italiano
United States
XS1909193150 ( in EUR )
